1-7 of 7
Maria Chiara Rossi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA1c Targets

Giuseppina T. Russo, Antonio Nicolucci, Giuseppe Lucisano, Maria Chiara Rossi, Antonio Ceriello, Francesco Prattichizzo, Valeria Manicardi, Alberto Rocca, Paolo Di Bartolo, Salvatore De Cosmo, Graziano Di Cianni, Riccardo Candido
Journal: Diabetes
Diabetes 2024;74(1):75–81
https://doi.org/10.2337/db24-0166
Published: 17 October 2024
View article titled, When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA<sub>1c</sub> Targets
Open the PDF for When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA<sub>1c</sub> Targets in another window
Meeting Abstracts

1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MONICA LAROSA, MARIA CHIARA ROSSI, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1804-PUB
https://doi.org/10.2337/db23-1804-PUB
Published: 23 June 2023
View article titled, 1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study
Meeting Abstracts

84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP
Journal: Diabetes
Diabetes 2023;72(Supplement_1):84-LB
https://doi.org/10.2337/db23-84-LB
Published: 20 June 2023
View article titled, 84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study
Meeting Abstracts

779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

RAFFAELE NAPOLI, MONICA LAROSA, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, RICCARDO CANDIDO, RESTORE-G STUDY GROUP
Journal: Diabetes
Diabetes 2023;72(Supplement_1):779-P
https://doi.org/10.2337/db23-779-P
Published: 20 June 2023
View article titled, 779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study
Meeting Abstracts

87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MONICA LAROSA, MARIA CHIARA ROSSI, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP
Journal: Diabetes
Diabetes 2022;71(Supplement_1):87-LB
https://doi.org/10.2337/db22-87-LB
Published: 01 June 2022
View article titled, 87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study
Meeting Abstracts

109-LB: Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Naïve Type 2 Diabetes Adults: RESTORE-2 Real-World Study

GIAN PAOLO FADINI, RAFFAELLA BUZZETTI, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, DOMENICO CUCINOTTA, ON BEHALF OF RESTORE-2 STUDY GROUP
Journal: Diabetes
Diabetes 2021;70(Supplement_1):109-LB
https://doi.org/10.2337/db21-109-LB
Published: 01 June 2021
View article titled, 109-LB: Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Naïve Type 2 Diabetes Adults: RESTORE-2 Real-World Study
Meeting Abstracts

110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study

RICCARDO CANDIDO, MONICA MODUGNO, ENRICO GABELLIERI, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, ON BEHALF OF ENSURE STUDY GROUP
Journal: Diabetes
Diabetes 2021;70(Supplement_1):110-LB
https://doi.org/10.2337/db21-110-LB
Published: 01 June 2021
View article titled, 110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study